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Anti-inﬂammatoryAbstract New series of 3,4-diaryl-2-thioxoimidazolidin-4-ones and 3-alkylthio-4,5-diaryl-4H-
1,2,4-triazoles were designed, synthesized and evaluated for their activity as anti-inﬂammatory
agents. Compounds 20, 21, 23 and 34 are highly selective inhibitors of COX-2 enzyme at a concen-
tration of 100 mM relative to celecoxib, the standard reference. (±)-3-(4-Phenoxy-phenyl)-5-phe
nyl-2-thioxoimidazolidin-4-ones 23 exhibited the most active anti-inﬂammatory agent.
ª 2015 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Non-steroidal anti-inﬂammatory drugs (NSAIDs) constitute
one of the most widely used classes of drugs. NSAIDs 1–11
are commonly used as anti-inﬂammatory, analgesic,antirheumatic and antipyretic agents (Rodriguez et al., 1998);
(Chart 1). The common mechanism of action for NSAIDs is
inhibition of the synthesis of PGs by inhibiting the key
regulatory cyclooxygenase ‘‘COX’’ enzyme. In 1989, it was
determined that there were at least 2 isoforms of cyclooxyge-
nase: COX-1, or prostaglandin H1 synthase, and COX-2, pros-
taglandin H2 synthase. COX-1 is expressed in most tissues,
regulates physiological processes such as gastric cytoprotec-
tion, kidney function, and platelet aggregation, and is stimulated
by growth factors and hormones. It has been called the ‘‘house
keeping’’ enzyme (Sperling, 1995; Kulkarni and Jain, 2005;
Singh, 1998; Graumlich, 2001; Lee, 2011; Noble et al., 2000).
However, the unfavorable side effect of NSAID drugs
mainly is the whole GI tract damage including a wide spectrums poten-
Chart 1 Classic NSAIDs.
2 D.A. Al-Turki et al.of lesions. About 1–2% of NSAID users experienced a serious
GI complication during treatment due to the inhibition of
COX-1 (Grifﬁn et al., 1991; Hollander, 1994; Laine, 1996;
Scheiman, 1996).
A new generation of selective cyclooxygenase-2 (COX-2)
inhibitors allowed the desired synthesis of cytoprotective pros-
taglandins, in conjunction with a simultaneous inhibition of
pro-inﬂammatory prostaglandin synthesis, thereby reducing
dyspepsia and ulceration. COX-2 selective inhibitors are
also known to suppress synthesis of prostacyclin, a potent
vasodilator and gastro-protective. They are validated as anti-
inﬂammatory therapeutics for the treatment of rheumatoid
arthritis with less gastrointestinal and renal toxicity
(Crofford et al., 2000; Gauthier et al., 2006; Navidpour
et al., 2006; Chrischilles and Wallace, 1993; DuBois et al.,
1988).
The pharmacophore structural features of the selective
COX-2 inhibitors are possessing a central heterocyclic ﬁve
membered ring system bearing two vicinal aryl moieties, such
as pyrazole (celcoxib, 12), 2(5H)furanone (refecoxib, 13), and
isoxazole (valdecoxib, 14) (Chart 2) (Penning et al., 1997; Li
et al., 1999; Talley et al., 2000a,b; Li et al., 2003). Also, the
substituted sulfonyl group is considered one of the pharma-
cophoric moieties responsible for the selective recognition of
the key amino acid residues at COX-2 active site pocket.
On the basis of these considerations, and in view of
the reported COX-2 inhibitory activity of certain
2-thioimidazolidin-4-one derivatives (Gauthier et al., 2006), aPlease cite this article in press as: Al-Turki, D.A. et al., Design, synthesis, molecular m
tial selective cyclooxygenase-2 (COX-2) inhibitors. Saudi Pharmaceutical Journal (2series of (±)-2-thioxoimidazolidin-4-ones of the general struc-
ture (A) bearing two aryl moieties at 3- and 5-positions of the
imidazolidine ring and carrying different substituents on the
3-aryl residue was synthesized. COX-2 inhibitory potency of
several 1,2,4-triazole derivatives was evaluated (Maxwell
et al., 1984; Gosowami et al., 1984; Amir and Shikla, 2004).
Accordingly, certain 4,5-diaryl-4H-1,2,4-triazoles of the
general structure (B) and (C) possessing C3-thio and alkylthio
substituents and carrying a methylsulfonyl moiety in the
4-position of one aryl moiety were synthesized. In addition, and
in order to enhance COX-2 selectivity, the benzylthio derivatives
(D) were synthesized. The proposed compounds have a character-
istic molecular pattern and bulk volume to fulﬁll the pharma-
cophoric requirements for better recognition at the COX-2
binding active site. The newly synthesized analogs were evaluated
for their COX selectivity and their anti-inﬂammatory activity.2. Chemistry
To spotlight on the signiﬁcance of the functional groups that
will be used as a key to identify the difference in recognition
in both COX-1 and COX-2 active sites and to achieve proper
selective COX-2 inhibitors, Schemes 1 and 2 were used to
prepare different series of (±)-3-(Substituted phenyl)-5-phe
nyl-2-thioxo-imidazolidin-4-ones 20–23, 1-(4-methylsulfonyl
phenyl)-4-substituted phenyl-2,4-dihydro-3H-1,2,4-triazole-3-
thiones 29–32, and 3-(4-methyl or chloro-benzylthio)-4-odeling and biological evaluation of novel diaryl heterocyclic analogs as poten-
015), http://dx.doi.org/10.1016/j.jsps.2015.07.001
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Design, synthesis, molecular modeling and biological evaluation of novel diaryl heterocyclic analogs 3substituted phenyl-5-(4-methylsulfonyl)-4H-1,2,4-triazoles 33
and 34.
(±)-3-(Substituted phenyl)-5-phenyl-2-thioxoimidazolidin-
4-ones 20–23 were prepared following the reported procedures
(Gauthier et al., 2006). The isothiocyanate derivatives 15–18
were reacted with a solution of (±)-a-phenylglycine 19 in 1:1
water/pyridine mixture at alkaline pH, followed by acidiﬁca-
tion with 1N hydrochloric acid. The reaction yielded the
desired ﬁnal compounds 20–23, Table 1. The crude products
were puriﬁed by applying preparative thin layer chromatogra-
phy using CHCl3:CH3OH (7:3, v/v).
In the present work methyl 4-methyl sulfonyl benzoate ester
was easily prepared following the classical esteriﬁcation
method (El-Emam and Ibrahim, 1991), by heating 4-methyl
sulfonyl benzoic acid with pure methanol in the presence ofPlease cite this article in press as: Al-Turki, D.A. et al., Design, synthesis, molecular m
tial selective cyclooxygenase-2 (COX-2) inhibitors. Saudi Pharmaceutical Journal (2sulfuric acid as a dehydrating agent to yield the desired ester
in 98% yield. The target hydrazide 24 was prepared in high
yield by heating the methyl ester with hydrazine hydrate in
ethanol (El-Emam and Ibrahim, 1991). The acid hydrazide
24 was allowed to react with the appropriate isothiocyanate
in ethanol to obtain the corresponding thiosemicarbazides
25–28. Compounds 25–28 were reﬂuxed in saturated aqueous
sodium carbonate solution to afford the corresponding target
compounds 29–32.
Alkylation of 5-(4-methylsulfonyl phenyl)-4-substituted
phenyl-2,4-dihydro-3H-1,2,4-triazol-3-thiones 30 and 31 was
achieved through utilizing anhydrous potassium carbonate in
ethanol, followed by treatment with methyl iodide or p-
chlorobenzyl chloride to afford the corresponding alkylated
compounds 33 and 34.odeling and biological evaluation of novel diaryl heterocyclic analogs as poten-
015), http://dx.doi.org/10.1016/j.jsps.2015.07.001
Table 1 Percentage inhibitory activity against COX-1, COX-2 and Percentage increase in right paw weight carrageenan-induced
edema of the tested compounds.
Compd R or R1 R2 % Inhibition % Increase in right paw weight
COX-1 COX-2
Celecoxib – – – 80.6 66.2 ± 12.6
20 2-OCH3 – 0 49.3 Toxic
21 4-OCH3 – 0 62.9 37.0 ± 5.5
*
22 4-SCH3 – 0 28.8 Toxic
23 4-OPh – 0 59.6 16.6 ± 4.3**
29 2-OCH3 – 7.0 3.9 74.3 ± 5.7
30 3-OCH3 – 0 0 71.0 ± 4.2
31 4-SCH3 – 0 0 60.0 ± 13.8
32 4-Oph – 0 0 68.8 ± 11.7
33 3-OCH3 4-Cl-Bn 0 0 50.8 ± 14.9
34 4-SCH3 4-Cl-Bn 0 60.1 68.6 ± 6.9
For COX-1, COX-2 inhibition, all compounds were tested at a concentration of 100 lM, except the standard (celecoxib) which was used at
50.0 lM.
For carrageenan-induced paw edema data are expressed as mean ± standard error of mean (SEM), where (n= 4) represents the number of
animals.
* p< 0.05 compared with control group using one-way ANOVA followed by Dunnett’s post-hoc test.
** p< 0.01 compared with control group using one-way ANOVA followed by Dunnett’s post-hoc test.
4 D.A. Al-Turki et al.3. Results and discussion
3.1. In vitro COXs inhibitory effect and selectivity of tested
compounds
The effect of the tested compounds on COX-1 and COX-2
activity was carried out using a commercially available COX
inhibitor screening enzyme immuno-assay (EIA) kit Pradelles
et al., 1985. The results of this assay (Table 1) showed that
compounds 20, 21, 23 and 34 are highly selective inhibitors
of COX-2 enzyme. Although these compounds were tested at
a high concentration (100 lM), no inhibition of COX-1 activ-
ity was detected, supporting the conclusion that these com-
pounds are highly selective against COX-2. Conversely, other
compounds were inactive against either COX-1 or COX-2.3.2. In vivo anti-inﬂammatory effect of tested compounds
Subplantar injection of carrageenan in the rat paw elicited an
inﬂammatory response that was characterized by an increase in
the right paw weight (Winter et al., 1962; Mielens et al., 1968).
Pre-treatment of rats with compound 23 resulted in a signiﬁ-
cant decrease in the carrageenan-induced paw edema. The %
increase in the right paw edema was signiﬁcantly lower than
that of control group (Table 1). The obtained results suggest
that compound 23 is active anti-inﬂammatory in vivo.
Conversely, pre-treatment of rats with other compounds did
not affect the carrageenan-induced paw edema signiﬁcantly.
Moreover, compounds 20 and 22 were toxic to the animals
at the tested dose (150 mg kg1) showing symptoms of CNS
stimulation.
Considering the results of both in vitro and in vivo experi-
ments revealed that, compound 23 is a highly selective COX-
2 inhibitor with active anti-inﬂammatory effect (see Fig. 1).Please cite this article in press as: Al-Turki, D.A. et al., Design, synthesis, molecular m
tial selective cyclooxygenase-2 (COX-2) inhibitors. Saudi Pharmaceutical Journal (23.3. Molecular modeling study
The binary complex of the cyclooxygenase-2 enzyme (1CX2)
coupled with the selective COX-2 inhibitor; SC-558 was used
as a reference to modeling and docking study (Fig. 2).
Studying the hydrogen bonding interaction of the pyrazole
hetero-ring of SC558 with the 1CX2 active site revealed that
the N1 of the pyrazole ring contributed preferable hydrogen
bonds with the key pocket residue Tyr355. The sulfonyl oxy-
gen and the terminal amino group conferred three H-bonds
with the ‘catalytic triad’ residues of 1CX2 pocket Phe518,
His90 and Arg513, respectively.
Comparative computational study was performed to the
designed compounds 20–23 and 29–34 to examine their degree
of selective recognition at the binding active site with the
conserved amino acids of both COX-1 and COX-2 binding
pockets. Compound 20 with the 2-methoxy substituted group
showed hydrogen binding recognition with Leu352, which is
considered one of the common shared conserved residues in
both COX-1 and COX-2 binding pockets. However, com-
pound 20 showed high degree of recognition with the key
amino acid residues of COX-2 pocket namely Tyr355,
Val523 and Ala527 and that is in agreement with the in vitro
binding data (Fig. 3).
Comparative binding study of compound 23 indicated that
the 4-phenoxy substitution forced the stabilization at W-
shaped conformation that allows the terminal phenoxy group
to be directed toward wide edge of the hydrophobic binding
cavity. This conformational organization enhances the overall
interactive recognition with the key amino acid residues of
COX-2, and as a result imidazole ring was hanged with three
stable hydrogen bonds with Ala527, Leu352 and Val523, the
key residues present mainly in COX-2 binding pocket. The
three phenyl rings of the 23 were stabilized within the lipophilic
cavity where the van der wall interaction and the hydrophobicodeling and biological evaluation of novel diaryl heterocyclic analogs as poten-
015), http://dx.doi.org/10.1016/j.jsps.2015.07.001
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Figure 2 (a) Crystal structure of the non-selective COX-1 inhibitor 1MM (1PGF) showing the putative hydrogen bonding at the binding
active site. (b) Crystal structure of the selective COX-2 inhibitor showing the putative hydrogen bonding at the 1CX2 active site. With its
docked ligand; SC-558.
Design, synthesis, molecular modeling and biological evaluation of novel diaryl heterocyclic analogs 5interaction were established due to the presence of Tyr348,
Tyr385 and Tyr355. The phenoxy oxygen performed electro-
static interaction with the amino acid Ser353, the one of the
conserved residues at the selective binding pocket (Fig. 4).
Compound 23 showed proper recognition that goes properly
with its biological effect in both in vitro and in vivo screenings.
The triazole analogs including compounds 29–34 showed
no selectivity toward COX-1. This group of compounds isPlease cite this article in press as: Al-Turki, D.A. et al., Design, synthesis, molecular m
tial selective cyclooxygenase-2 (COX-2) inhibitors. Saudi Pharmaceutical Journal (2characterized by the presence of terminal sulfonyl moiety that
was considered crucial in the compound’s recognition with
three conserved amino acid residues namely His90, Arg513
and Phe518. Modeling study of the binding mode of com-
pound 29 indicated that, methyl-sulfonyl function performed
conformational recognition with Ile517, Gln192, His90, while
the terminal 2-methoxy group accomplished the binding with
Ser530 (Fig. 4).odeling and biological evaluation of novel diaryl heterocyclic analogs as poten-
015), http://dx.doi.org/10.1016/j.jsps.2015.07.001
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Figure 3 Comparative binding recognition of compound 20 at the two binding pockets of (a) COX-1 and (b) COX-2.
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Figure 4 Comparative binding recognition of compound 23 at the two binding pockets of (a) COX-1 and (b) COX-2.
6 D.A. Al-Turki et al.Compound 30 stabilized within the COX-2 binding pocket
by the interaction with 3-methoxy group and the correspond-
ing Tyr385 and Tyr355. The polar sulfonyl group also
performed network of hydrogen bonding interaction with
three conserved residues namely Arg513, Phe518 and His90.
In compounds 31 and 32, the methoxy substitution has been
changed to a methylthio or a phenoxy group. This alteration
led to a change in the binding style but maintained the
minimum common feature required for recognition within
the binding pocket, mainly the sulfonyl function group.
Compounds 33 and 34 substituted with the 4-chlorobenzyl
group allowed the stabilization of the conﬁguration by lipophi-
lic interaction with the lipophilic pocket residues where the
benzyl group oriented in a manner that allows the lipophilic
lattice from the surrounding residues Phe205, Tyr385 and
Tyr 348 (Fig. 5).
4. Experimental
Experimental synthesis has been done in the chemistry labora-
tory at pharmaceutical department; faculty of pharmacy; King
Saud University; Female sector. All reagents and solvents were
obtained from commercial suppliers and were used withoutPlease cite this article in press as: Al-Turki, D.A. et al., Design, synthesis, molecular m
tial selective cyclooxygenase-2 (COX-2) inhibitors. Saudi Pharmaceutical Journal (2further puriﬁcation. Melting points (C) were determined in
open glass capillaries using Branstead 9001 electrothermal
melting point apparatus and are uncorrected. Elemental
analyses were recorded on a PERKIN-ELMER 2400 C,H,N
elemental analyzer. NMR spectra were obtained on a Bruker
AC 500 ultra shield NMR spectrometer (Fallanden,
Switzerland) at 500.13 MHz for 1H and 125.76 MHz for 13C,
and the chemical shifts are expressed in d (ppm) downﬁeld
from tetramethylsilane (TMS) as internal standard; coupling
constant (J) are expressed in Hz. Deuterio-chloroform
(CDCl3) and deuteriodimethyl sulfoxide (DMSO_d6) were
used as solvents. Mass spectral (MS) data were obtained on
a Perkin Elmer, Clarus 600 GC/MS mass spectrometers.
Carrageenan and dimethylsulfoxide (DMSO) were purchased
from Sigma Chemical Co., St. Louis, MO, USA. Celecoxib
was obtained from Pﬁzer Inc., NY, USA. COX inhibitor
screening assay kit was obtained from Cayman Chemical
Company (Ann Arbor, MI, USA). Male Sprague–Dawley rats
weighing 200 ± 30 g from Mansoura University Animal
House (Mansoura, Egypt) were used.
All animal housing, care and treatment were strictly carried
out in accordance with the University Guidelines for the Care
and Use of Laboratory Animals. Food was withheld 12 hodeling and biological evaluation of novel diaryl heterocyclic analogs as poten-
015), http://dx.doi.org/10.1016/j.jsps.2015.07.001
29 30
31 32
33
34
Figure 5 Docking of the triazole analogs; 33 and 34 at the binding pocket of COX-2.
Design, synthesis, molecular modeling and biological evaluation of novel diaryl heterocyclic analogs 7before the experiment, with free access to water. Tested com-
pounds were ﬁrst dissolved in (DMSO) and diluted into reaction
buffer (in vitro experiment) using celecoxib as reference standard.
Immediately before in vivo experiment, tested compounds
were ﬁrst dissolved in (DMSO) and diluted 0.5%Please cite this article in press as: Al-Turki, D.A. et al., Design, synthesis, molecular m
tial selective cyclooxygenase-2 (COX-2) inhibitors. Saudi Pharmaceutical Journal (2carboxymethylcellulose. Carrageenan was dissolved as a 1%
in saline and left overnight.
All modeling experiments were conducted with Hyperchem
6.03 package from Hypercube and Moelgro molecular viewer
(Hyperchem, 1999; Molegro Virtual Docker MVD, 2007).odeling and biological evaluation of novel diaryl heterocyclic analogs as poten-
015), http://dx.doi.org/10.1016/j.jsps.2015.07.001
8 D.A. Al-Turki et al.4.1. Synthesis of (±)-3-(substituted phenyl)-5-phenyl-2-
thioxoimidazolidin-4-ones (20–23)
(±)-a-Phenylglycine (1.5 g; 9.9 mmol) is suspended in a mix-
ture of 1:1 pyridine/H2O (60 ml), warmed to 40 C and
adjusted to pH 9 with sodium carbonate solution 1N. The
required isothiocyanate derivative (14.9 mmol) is added por-
tion wise over 1 h with stirring. Three hours later, the solvents
are evaporated under reduced pressure, and the crude residue
is dissolved in water (100 ml). The solution was extracted three
times with toluene (3 · 50 ml) and then acidiﬁed with
hydrochloric acid 1N solution. The formed precipitate is
extracted with ethyl acetate (3 · 50 ml). The organic layers
were combined, washed with water, dried over anhydrous
magnesium sulfate and evaporated under vacuum. The
obtained residue was puriﬁed by applying preparative thin
layer chromatography using CHCl3:CH3OH (7:3, v/v) to
obtain the target 3, 5-diaryl-2-thioxoimidazolidin-4-ones (20–
23).
4.1.1. (±)-3-(2-Methoxyphenyl)-5-phenyl-2-
thioxoimidazolidin-4-one 20
Yield: 73%, mp: 193–194 C. MS: m/z; M+ 298 (5%). 1H
NMR (DMSO-d6), d 3.71 (s, 3H, OCH3), 5.49 (s, 1H,
ANHACHACOA), 7.02 (d, 1H, ArH), 7.10–7.23 (m, 3H,
ArH), 7.30–7.45 (m, 5H, ArH),10.82 (brd, 1H, NH).
Analysis for C16H14N2O2S (298.36): C, 64.41; H, 4.73;
Found: C, 64.20; H, 4.50.
4.1.2. (±)-3-(4-Methoxyphenyl)-5-phenyl-2-
thioxoimidazolidin-4-one 21
Yield: 95%, mp: 197–199 C. MS: m/z; M+ 298 (7%). 1H
NMR (DMSO-d6), d 3.79 (s, 3H, OCH3), 5.57 (s, 1H,
ANHACHACOA), 6.82 (d, 2H, J= 8.5 Hz, ArH), 7.20 (d,
2H, 7.5 Hz, ArH), 7.35–7.45 (m, 5H, ArH), 10.97 (brd, 1H,
NH). 13C NMR: d 55.9, 63.1, 114.5, 126.3, 126.4, 127.6,
129.5, 130.5, 135.0, 159.7, 173.32 (C‚O), 183.7 (C‚S).
Analysis for C16H14N2O2S (298.36): C, 64.41; H, 4.73;
Found: C, 64.33; H, 4.43.
4.1.3. (±)-3-(2-Methylthiophenyl)-5-phenyl-2-
thioxoimidazolidin-4-one 22
Yield: 15%, mp: 214–215 C. MS: m/z; M+; 314(10%). 1H
NMR (DMSO-d6), d 2.48 (s, 3H, SCH3), 5.56 (s, 1H,
ANHACHACOA), 7.22–7.30 (m, 5H, ArH), 7.32–7.35 (m,
2H, ArH), 7.38–7.44 (m, 2H, ArH), 10.95 (brd, 1H, NH).
Analysis for C16H14N2OS2 (314.43): C, 61.12; H, 4.49;
Found C, 61.20; H, 4.34.
4.1.4. (±)-3-(4-Phenoxyphenyl)-5-phenyl-2-
thioxoimidazolidin-4-one 23
Yield: 50%, mp: 250–252 C. MS: m/z; M+; 360(4%). 1H
NMR (DMSO-d6), d 5.61 (s, 1H, imidazolidine-H), 7.09–7.12
(m, 4H, ArH), 7.19–7.22 (m, 1H, ArH), 7.36 (d, 2H,
J= 8.5 Hz, ArH), 7.39–7.49 (m, 7H, ArH), 11.04 (brd, 1H,
NH). 13C NMR: d 63.2, 118.5, 119.9, 124.6, 127.6, 128.7,
129.3, 129.5, 130.7, 131.0, 134.9, 156.3, 157.6, 173.2 (C‚O),
183.4 (C‚S). Analysis for C21H16N2O2S (360.43): C, 69.98;
H, 4.47; Found C, 69.85; H, 4.27.Please cite this article in press as: Al-Turki, D.A. et al., Design, synthesis, molecular m
tial selective cyclooxygenase-2 (COX-2) inhibitors. Saudi Pharmaceutical Journal (24.2. Synthesis of 1-(4-methylsulfonyl benzoyl)-4-substituted
phenyl-thiosemi-carbazide (25–28)
To a solution of 4-methylsulfonylbenzoic acid hydrazide 24
that was prepared as reported (El-Emam and Ibrahim, 1991)
(0.32 g, 1.5 mmol) in absolute ethanol (5 ml), the appropriate
isothiocyanate (1.55 mmol) was added and the mixture was
stirred at room temperature for 24 h. The formed precipitate
was ﬁltered, dried and recrystallized from ethanol to give the
desired products 25–28 as white solids.
4.2.1. 1-(4-Methylsulfonyl benzoyl)-4-(2-methoxyphenyl)
thiosemicarbazide 25
Yield: 59%, mp: 180 C. MS: m/z; M+; 379 (10%). 1H NMR
(DMSO-d6), d 3.28 (s, 3H, SO2CH3), 3.75 (s, 3H, OCH3), 6.94–
7.17 (m, 4H, ArH), 8.02–8.16 (m, 4H, ArH), 9.32 (brd, 1H,
NH), 9.90 (brd, 1H, NH), 10.83 (brs, 1H, NH). Analysis for
C16H17N3O4S2 (379.45): C, 50.64; H, 4.52; Found: C, 50.60;
H, 4.49.
4.2.2. 1-(4-Methylsulfonyl benzoyl)-4-(3-methoxyphenyl)
thiosemicarbazide 26
Yield: 75%, mp: 175 C. MS: m/z; M+; 379 (18%). 1H NMR
(DMSO-d6), d 3.28 (s, 3H, SO2CH3), 3.75 (s, 3H, OCH3), 6.75–
7.24 (m, 4H, ArH), 8.08–8.18 (m, 4H, ArH), 9.80 (brd, 2H, 2
NH), 10.80 (brd, 1H, NH). Analysis for C16H17N3O4S2
(379.45): C, 50.64; H, 4.52; Found: C, 50.69; H, 4.35.
4.2.3. 1-(4-Methylsulfonyl benzoyl)-4-(4-methylthiophenyl)
thiosemicarbazide 27
Yield: 100%, mp: 200 C. MS: m/z; M+; 395 (5%). 1H NMR
(DMSO-d6), d 2.47 (s, 3H, SCH3), 3.28 (s, 3H, SO2CH3), 7.24–
741 (m, 4H, ArH), 8.08–8.19 (m, 4H, ArH), 9.79 (brs, 2H,
NH), 10.80 (brs, 1H, NH). Analysis for (395.52): C, 48.59;
H, 4.33; Found: C, 48.55; H, 4.35.
4.2.4. 1-(4-Methylsulfonyl benzoyl)-4-(4-phenoxyphenyl)
thiosemicarbazide 28
Yield: 68%, mp: 200 C. MS: m/z; M+; 441 (14%). 1H NMR
(DMSO-d6), d 3.28 (s, 3H, SO2CH3), 6.95–7.25 (m, 4H, ArH),
7.35–7.43 (m, 5H, ArH), 8.03–8.23 (m, 4H, ArH), 9.83 (brd,
2H, NH), 10.82 (brd, 1H, NH). Analysis for C21H19N23O4S2
(441.52): C, 57.13; H, 4.34; Found: C, 57.35; H, 4.350.
4.3. Synthesis of 5-[4-(methylsulfonyl)phenyl]-4-substituted
phenyl-2,4-dihydro-3H-1, 2, 4-triazol-3-thiones (29–32)
A mixture of compounds (25–28, 1.5 mmol) and saturated
aqueous sodium carbonate solution (15 ml) were heated under
reﬂux with stirring for 12 h. The obtained solution was cooled
and neutralized with hydrochloric acid 10%. The formed pre-
cipitate was ﬁltered, washed with water, dried and then recrys-
tallized from ethanol to give compounds 29–32.
4.3.1. 5-(4-Methylsulfonylphenyl)-2-methoxyphenyl-2,4-dihydro-
3H-1,2,4-triazol-3-thione 29
Yield: 45%, mp: >300 C. MS: m/z; M+; 361 (3%). 1H NMR
(DMSO-d6), d 3.21(s, 3H, SO2CH3), 3.55(s, 3H, OCH3), 7.13–odeling and biological evaluation of novel diaryl heterocyclic analogs as poten-
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NH). Analysis for C16H15N3O3S (361.44): C, 53.17; H, 4.18;
Found C, 53.22; H, 4.45.
4.3.2. 5-(4-Methylsulfonylphenyl)-3-methoxyphenyl-2,4-
dihydro-3H-1,2,4-triazol-3-thione 30
Yield: 60%, mp: 267 C. MS: m/z; M+; 361 (7%). 1H NMR
(DMSO-d6), d 3.22 (s, 3H, SO2CH3), 3.74 (s, 3H, OCH3),
6.92–7.33 (m, 4H, ArH), 7.55–7.92 (m, 4H, ArH), 14.28 (brd,
1H, NH). 13C NMR: d 43.6 (SO2CH3), 56.0 (OCH3), 115.3,
115.7, 121.2, 127.6, 129.5, 130.7, 131.0, 135.7, 142.6, 149.6,
160.2, 169.5. Analysis for C16H15N3O3S (361.44): C, 53.17;
H, 4.18; Found C, 53.25; H, 4.30.
4.3.3. 5-(4-Methylsulfonylphenyl)-4-methylthiophenyl-2,4-
dihydro-3H-1,2,4-triazol-3-thione 31
Yield: 92%, mp: 255 C. MS: m/z; M+; 377 (1%). 1H NMR
(DMSO-d6), d2.51(s, 3H, SCH3), 3.23(s, 3H, SO2CH3), 7.34–
7.65 (m, 4H, ArH), 7.70–7.93 (m, 4H, ArH), 14.27 (brs, 1H,
NH). 13C NMR: d 14.8 (SCH3), 43.6(SO2CH3), 126.5, 127.6,
129.5, 129.6, 131.0, 131.2, 141.0, 142.7, 149.7, 169.7. Analysis
for C16H15N3O2S3 (377.5): C, 50.91; H, 4.01; Found C,
50.85; H, 4.00.
4.3.4. 5-(4-Methylsulfonylphenyl)-4-phenoxyphenyl-2,4-
dihydro-3H-1,2,4-triazol-3-thione 32
Yield: 54%, mp: 246 C. MS(EI): m/z; M+; 423 (3%). 1H
NMR (DMSO-d6), d 3.28 (s, 3H, SO2CH3), 7.04–7.41 (m,
4H, ArH), 7.44–7.75 (m, 4H, ArH), 7.88–7.99 (m, 5H, ArH),
14.31 (brd, 1H, NH). Analysis for C21H17N3O3S2 (423.51):
C, 59.56; H, 4.05; Found: C, 59.50; H, 4.00.
4.4. Synthesis of 3-(alkyl or aralkyl thio)-4-substituted phenyl-
5-(4-methyl-sulfonyl)-4H-1, 2, 4-triazoles (33 and 34)
The appropriate halides namely p-chlorobenzyl chloride
(0.5 mmol) was added to a solution of (30, 31, 0.5 mmol) in
ethanolic sodium carbonate 2% (5 ml). The mixture was stir-
red and heated under reﬂux for 24 h. The solvent was evapo-
rated under reduced pressure; the obtained residue was
washed with water, dried and then recrystallized from ethanol
to give the title compounds 33 and 34.
4.4.1. 3-(4-Chloro-benzylthio)-4-(3-methoxyphenyl)-5-(4-
methylsulfonyl)-4H-1,2,4-triazole 33
Yield: 38%, mp: 120 C. MS: m/z; M+; 486 (4%). 1H NMR
(CDCl3), d 3.03 (s, 3H, SO2CH3), 3.80 (s, 3H, OCH3), 4.54
(s, 2H, CH2Ph), 6.75–7.78 (m, 4H, ArH), 7.78–7.80 (m, 4H,
ArH), 7.85–7.87 (m, 4H, ArH). Analysis for
C23H20ClN3O3S2 (486.01): C, 56.84; H, 4.15; Found: C,
56.80; H, 4.11.
4.4.2. 3-(4-Chloro-benzylthio)-4-(4-methylthiophenyl)-5-(4-
methylsulfonyl)-4H-1,2,4-triazole 34
Yield: 38%, mp: 175–8 C. MS: m/z; M+; 502 (7%). 1H NMR
(CDCl3), d2.51 (s, 3H, SCH3), 3.02 (s, 3H, SO2CH3), 4.51 (s,
2H, CH2Ph), 7.08–7.22 (m, 4H, ArH), 7.25–7.77 (m, 4H,
ArH), 7.79–7.87 (m, 4H, ArH). 13C NMR: d 15.1 (SCH3),
36.5 (CH2Ph), 44.2 (SO2CH3), 127.0, 127.3, 127.7, 128.8,Please cite this article in press as: Al-Turki, D.A. et al., Design, synthesis, molecular m
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154.0. Analysis for C23H20ClN3O2S3 (502.07): C, 55.02; H,
4.02; Found: C, 55.10; H, 4.09.
5. Biological evaluations
5.1. In vitro COX-1 and COX-2 inhibition assay
The assay includes both bovine COX-1 and human recombi-
nant COX-2 enzymes to perform screening of isozyme-
speciﬁc inhibitors using celecoxib was used as standard
(Pradelles et al., 1985). The tested compounds were added to
both COX-1 and COX-2 with the substrates and buffers to
perform the COX reaction according to kit instructions. The
COX-derived PGH2 produced in the COX reaction is reduced
to the more stable PGF2a by SnC12, and the amount of PGF2a
was quantiﬁed via enzyme immunoassay (EIA) using a broadly
speciﬁc antiserum that binds to all the major PG compounds
according to kit instructions. The product of the enzymatic
reaction has a distinct yellow color that was absorbed strongly
at 412 nm. The intensity of the color, which determined spec-
trophotometrically, is proportional to the amount of PG tracer
bound to the well, which is inversely proportional to the
amount of free PG present in the well during the incubation.
Therefore, the more the inhibition of COX by any of the tested
compounds, the less PG produced, and the more absorbance
or color developed.
5.2. In vivo carrageenan-induced paw edema
This method was originally described by Winter et al. (1962)
and modiﬁed by Mielens et al. (1968). It is a model of acute
inﬂammation. Tested compounds were administered
(150 mg kg1) 1 h before injecting 0.1 ml of 1% carrageenan
into the subplantar region of the right hind paw. The left hind
paw of each rat received a subplantar injection of equal vol-
ume of normal saline. Control group received the vehicle
instead of tested compounds. After a further 3 h, the rats were
humanely killed by cervical dislocation and the hind paws
removed at the paw hairline (tibiotarsic articulation) and
weighed.
5.3. Data analysis
In vitro experiment, calculations and analysis of data were car-
ried out according to the reported instructions. The concentra-
tion of each sample was identiﬁed by extrapolating its %B/B0
on the standard curve, and then the % inhibition of COX-1
and COX-2 by each inhibitor was calculated.
For in vivo experiment, data were expressed as
mean ± standard error of mean (SEM), where (n) equals the
number of animals (rats). The carrageenan-induced paw
edema was calculated as following:
% Increase in right paw edema
¼ right paw weight left paw weight
left paw weight
 100
Signiﬁcant differences between groups were determined
with one-way ANOVA with Dunnett’s post-hoc test.odeling and biological evaluation of novel diaryl heterocyclic analogs as poten-
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6.1. COX-2 enzyme structure
Starting coordinate of the cyclooxygenase-2 enzyme, ‘‘1CX2’’
in complex with a selective inhibitor, SC-558, code ID 1CX2,
was obtained from the Protein Data Bank of Brookhaven
National Laboratory, Fig. 2 (Kurumbail et al., 1996).
6.2. COX-1 enzyme structure
Starting coordinate of the cyclooxygenase-1 enzyme, ‘‘1PGF’’
in complex with a non-selective inhibitor, Iodoindomethacin
‘‘IMM’’ codeID 1PGF, was obtained from the Protein Data
Bank of Brookhaven National Laboratory, Fig. 2 (Loll
et al., 1996).
6.3. The selective COX-2 inhibitor SC-558
The crystal structure of SC558 selective inhibitor was depicted
at the binding active site showing the putative hydrogen bond-
ing with the conserved amino acid residues.
6.4. COX-1 non-selective IMM
The crystal structure of 1MM non-selective inhibitor was cap-
tured at the binding active site showing the putative hydrogen
bonding with the surrounding amino acid residues.
6.5. Molecular structure of the synthesized imidazoles and
triazoles
The imidazole or triazole analogs (20–23 and 29–34) were con-
structed from fragment libraries in the Hyperchem program
followed by energy minimization using the ‘‘Amber force
ﬁeld’’. The partial atomic charges for each analog were assigned
with the semiempirical mechanical calculation method ‘‘AM1’’
implemented in Hyperchem 6.03. Conformational search was
performed around all the rotatable bonds with an increment
of 100 using conformational search module as implemented
in HyperChem 6.03 All the conformers were minimized until
the Root Mean Square (RMS) deviation was 0.01 kcal/mol A˚.
6.6. Docking and molecular geometrical optimization
Lowest energy conformer of each new analog ‘‘global-
minima’’ was docked into the two enzymes COX-1 and
COX-2 binding cavity 1CX2 & 1PGF. For each of the tested
analogs, energy minimizations were performed using 1000
steps of steepest descent, followed by conjugate gradient min-
imization to a RMS energy gradient of 0.01 kcal/mol A˚.
Hydrogen bonds with a bond length up to 3.5 A˚ were consid-
ered. The active site of the enzyme was deﬁned using a radius
of 8.0 A˚ around the ligands SC-558 and IMM.
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